で公開中です！詳しく見る

LENZ Therapeutics

LENZ

時価総額 $1.03億

3.27 USD

-0.30

8.4%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

3.26

-0.01

0.31%

1日

-8.4%

5日間

-10.16%

1か月

-21.01%

3か月

-32.99%

6か月

-66.08%

年初来

-79.56%

1年

-91.92%

5年間

-96.24%

10年間

-97.47%

概要： LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

従業員数： 152

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 10.5%

ニュートラル 84.2%

ネガティブ 5.3%

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ポジティブ

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

These beaten-down stocks could bounce back in January, if history is any guide

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています